Showing 221 - 240 results of 549 for search '"Pharmaceutics"', query time: 0.05s Refine Results
  1. 221

    Polypragmasy at treatment of <i>H. pylori</i> infection in patients with concomitant diseases of other organs and systems. How to prevent side effects related to drug interactions? by S. G. Burkov, N. V. Shornikova

    Published 2011-05-01
    “…As eradication therapy implicates addition to treatment of at least 3 pharmaceuticals of which antibiotics are strictly specified, it is extremely desirable to choose proton pump inhibitor (PPI) with lower affinity to cytochrome Р450. …”
    Get full text
    Article
  2. 222

    Daropeptide natural products by Suze Ma, Sijia Guo, Wei Ding, Qi Zhang

    Published 2024-04-01
    “…Cyclophane-containing peptides comprise an important group of macrocyclic peptides with unique structural properties and pharmaceutical relevance. Darobactin A is a ribosomally synthesized and post-translationally modified peptide (RiPP) antibiotic, which features an unusual biscyclophane moiety formed via the class-defining ether crosslink in addition to a carbon-carbon (C-C) crosslink. …”
    Get full text
    Article
  3. 223
  4. 224
  5. 225
  6. 226
  7. 227

    The South African guidelines on enuresis: 2024 update by A Adam, A Badenhorst, F Claassen, T de Maayer, M Fockema, J Fredericks, E Gottlich, J John, N Lala, J Lazarus, S Leahy, H N Lourens, S Maharaj, K M Mathabe, E M Moshokoa, S B A Mutambirwa, K L Petersen, M B Radzuma, A van der Merwe, I van Heerden, C A Zietsman, F Alyami, A Deshpande, G H H Smith

    Published 2024-11-01
    “…These options include behavioural modification, urotherapy, pharmaceutical therapy, alarm therapy, alternative therapies, neuromodulation, psychological support and biofeedback. …”
    Get full text
    Article
  8. 228

    Discussion of irritable bowel syndrome issue and functional constipations in reports of the 21st United European Gastroenterological Week (Berlin, 2013) by A. A. Sheptulin, M. A. Vizye-Khripunova

    Published 2014-09-01
    “….), that may progress under a mask of the functional intestinal disorders is required. The range of pharmaceuticals has been replenished by new agents (linaclotide, prucalopride), increasing efficacy of IBS and CFC treatment.Conclusion. …”
    Get full text
    Article
  9. 229
  10. 230

    Energy transfer aspects of chemically reactive Casson fluid between a conical gap of cone-disk system with multiple rotations by M. Qamar, M. Khan, A.S. Alqahtani, M.Y. Malik

    Published 2025-03-01
    “…Casson fluids have been widely used in engineering and biotechnology including, energy systems, polymer fluids, pharmaceuticals, chocolate, automotive industries, blood, and honey. …”
    Get full text
    Article
  11. 231

    Comparison of clinical and pharmacodynamic features of proton pump inhibitors efficacy in gastroesophageal reflux disease by O. A. Storonova, A. S. Trukhmanov

    Published 2015-12-01
    “…PPI are the most effective pharmaceuticals for treatment of acid-related diseases (ARD). …”
    Get full text
    Article
  12. 232

    Alcohol, alcoholism and related consequences by M. V. Mayevskaya

    Published 2013-12-01
    “…Successful campaign against alcoholism is possible only at application of all resources: strategy of the state, involvement of internist doctors in problem decision (application of motivational conversation technic), pharmaceutical therapy directed on reduction of amount alcoholic drinks.…”
    Get full text
    Article
  13. 233

    Control of atropoisomerism: an access to valuable compounds by Choppin, Sabine, Wencel-Delord, Joanna, Colobert, Françoise

    Published 2024-03-01
    “…Atropoisomerism is well-known in biaryls, however this phenomenon is encountered in many pharmaceutically relevant compounds such as heterobiaryl, diarylamines, benzamides and anilides.Currently four FDA-approved drugs are atropostable and many others are in clinical trials. …”
    Get full text
    Article
  14. 234

    Drug-induced liver injuries (Part 1) by S. F. Galimova

    Published 2012-06-01
    “…DILI can progress under the mask of all known acute and chronic liver diseases. Pharmaceuticals act as one of the leading causes of development of fulminant liver failure in many countries of the world. …”
    Get full text
    Article
  15. 235

    Efficacy of silymarinum at chronic diffuse liver diseases by A. V. Matvieiev, E. I. Konyaeva, N. V. Matvieieva

    Published 2011-09-01
    “…Analysis of literary data demonstrated, that silymarinum is a safe pharmaceutical and, despite of a plenty of clinical and experimental publications, its efficacy at alcoholic liver disease and primary biliary cirrhosis requires further studying as series of systematic reviews and metaanalyses are subject for discussion due to the absence of uniform methodological approaches, application of drugs with different pharmakokinetics and because of ignoring of evidencebased medicine requirements.Conclusion. …”
    Get full text
    Article
  16. 236

    Metabolomic profiles as a new understanding of disease processes by O. Yu. Zolnikova, M. S. Reshetova, M. N. Ivanova, V. T. Ivashkin

    Published 2022-05-01
    “…These results define new potential therapeutic strategies, making metabolomics useful for a wide range of biomedical and pharmaceutical research.Conclusion. Metabolomic profile changes in different types of diseases will help to improve understanding of the pathogenesis. …”
    Get full text
    Article
  17. 237

    The need for Open Labs for fostering interdisciplinarities in Modern Chemistry. Biocatalysis: a necessary tool for synthetic chemists by Martin, Juliette

    Published 2024-02-01
    “…However, enzymatic catalysis is a mature technology, and this should encourage more chemists to take further ownership and expand applications in modern chemistry.In the industrial sector, some pharmaceutical companies have been pioneers in the use and acceptance of biocatalysis for the unique properties that enzymes can deliver. …”
    Get full text
    Article
  18. 238
  19. 239
  20. 240